2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart …
Writing Committee Members, JA Joglar… - Journal of the American …, 2024 - jacc.org
Abstract Aim The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management
of Patients With Atrial Fibrillation” provides recommendations to guide clinicians in the …
of Patients With Atrial Fibrillation” provides recommendations to guide clinicians in the …
[HTML][HTML] Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia
Background In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: JACC: CardioOncology State-of-the-Art Review
Cardiovascular disease and cancer are the 2 leading causes of death worldwide. Emerging
evidence suggests common mechanisms between cancer and cardiovascular disease …
evidence suggests common mechanisms between cancer and cardiovascular disease …
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review
C Quartermaine, SM Ghazi, A Yasin, FT Awan… - Cardio Oncology, 2023 - jacc.org
Over the past decade, the treatment landscape of chronic lymphocytic leukemia (CLL) has
dramatically changed, shifting from cytotoxic chemotherapy to targeted therapies. Bruton's …
dramatically changed, shifting from cytotoxic chemotherapy to targeted therapies. Bruton's …
Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial
PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity
than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …
than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …
Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database
While multiple pharmacological drugs have been associated with myocarditis, temporal
trends and overall mortality have not been reported. Here we report the spectrum and main …
trends and overall mortality have not been reported. Here we report the spectrum and main …
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
ELEVATE-RR demonstrated noninferior progression-free survival and lower incidence of
key adverse events (AEs) with acalabrutinib vs ibrutinib in previously treated chronic …
key adverse events (AEs) with acalabrutinib vs ibrutinib in previously treated chronic …
Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial
PURPOSE Zanubrutinib is a potent, irreversible next-generation Bruton tyrosine kinase
(BTK) inhibitor designed to maximize BTK occupancy and minimize off-target kinase …
(BTK) inhibitor designed to maximize BTK occupancy and minimize off-target kinase …
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia
R Bennett, MA Anderson, JF Seymour - Journal of Hematology & Oncology, 2023 - Springer
Background The treatment landscape for chronic lymphocytic leukemia (CLL) continues to
undergo considerable evolution. Optimal selection of initial therapy from multiple effective …
undergo considerable evolution. Optimal selection of initial therapy from multiple effective …
Zanubrutinib: past, present, and future
In recent years, Bruton tyrosine kinase (BTK) inhibitors have provided significant advances
in the treatment of patients with B-cell malignancies. Ibrutinib was the first BTK inhibitor to be …
in the treatment of patients with B-cell malignancies. Ibrutinib was the first BTK inhibitor to be …